Epidemiology of cardiovascular disease and diabetes in 2026: expanding prevalence, escalating costs, and the limits of contemporary prevention

Abstract

The recently published 2026 American Heart Association Heart Disease and Stroke Statistics Update extends beyond routine surveillance to provide a systems-level diagnosis of contemporary cardiovascular medicine. When examined collectively, epidemiologic and economic data reveal that cardiovascular disease has evolved from an acute, episodic illness into a chronic, multisystem condition with profound population and fiscal consequences. Nearly half of US adults now meet criteria for cardiovascular disease when hypertension is included, underscoring that cardiovascular pathology has become a defining feature of aging rather than a condition affecting discrete subgroups. Despite declining age-adjusted mortality, prevalence continues to rise, driven by earlier onset of risk factors, improved survival, and prolonged disease duration. This epidemiologic success paradoxically fuels escalating healthcare expenditures, which now exceed $400 billion annually. Disease-specific analyses reinforce this structural challenge. Coronary heart disease has reached epidemiologic stability but remains fiscally unsustainable due to lifelong secondary prevention. Heart failure is the fastest-growing phenotype, reflecting cumulative cardiometabolic injury and exposing the limitations of reactive, hospitalization-centered care models. Stroke incidence has declined, yet prevalence and long-term costs are projected to surge as survival improves. Atrial fibrillation has emerged as a lifetime-risk condition with substantial downstream consequences that are incompletely captured by current cost estimates. Upstream drivers (diabetes, hypertension, and metabolic dysfunction) continue to worsen despite effective therapies, highlighting failures of implementation rather than pharmacology. The introduction of cardiovascular–kidney–metabolic syndrome provides an integrative framework that more accurately reflects contemporary risk and reveals important sex-specific vulnerabilities. Overall, these data demonstrate that knowledge is no longer the limiting factor; durable population health gains will require systemic prevention, integrated care, and policy alignment to translate scientific progress into sustainable outcomes.

Introduction: from surveillance report to systems diagnosis

The 2026 American Heart Association (AHA) Heart Disease and Stroke Statistics Update represents more than an annual epidemiologic snapshot. In aggregate, it functions as a diagnostic assessment of cardiovascular medicine as a system, exposing the widening gap between scientific capability and population-level outcomes [1]. When the disease-specific epidemiology and cost data are examined collectively, a consistent narrative emerges: cardiovascular disease (CVD) is no longer primarily an acute clinical problem but a chronic, multisystem, and economically destabilizing condition.

Despite decades of guideline refinement, pharmacologic innovation, and procedural advances, the overall prevalence of CVD continues to rise, upstream risk factors worsen, and healthcare expenditures accelerate [2, 3]. The 2026 update is therefore best interpreted not as a catalog of isolated diseases, but as evidence of a structural failure to translate cardiovascular knowledge into durable population health gains.

CVD as a population condition

As summarized in Table 1, nearly 49% of U.S. adults (approximately 130.6 million individuals) meet criteria for CVD when hypertension is included [1]. Even when hypertension is excluded, more than 24 million adults (8.2%) have established clinical CVD. These figures represent a fundamental shift in how CVD should be conceptualized: it is no longer a disease of subgroups, but a defining characteristic of middle and older age in the United States [4].

Table 1.

Overall cardiovascular disease (CVD)

Measure	Estimate
Prevalence (including hypertension)	48.9% (130.6 million)
Prevalence (excluding hypertension)	8.2% (24.5 million)
Annual economic burden	$414 billion

This epidemiologic framing is not merely semantic. Hypertension, dyslipidemia, and metabolic dysfunction are increasingly diagnosed earlier in life, persist for decades, and interact synergistically with aging [5]. As a result, the “CVD patient” is no longer a discrete clinical category but a statistical norm.

The annual economic burden of $414 billion attributed to CVD (Table 1) underscores the systemic implications of this prevalence. Importantly, these estimates incorporate both direct medical expenditures and indirect costs due to lost productivity, consistent with established cost-of-illness methodology [6].

The persistence of such costs despite declining age-adjusted mortality highlights a central paradox: success in prolonging life has increased the cumulative cost of cardiovascular care, without a corresponding reduction in disease incidence.

Hypertension and diabetes: the upstream engines of CVD

Hypertension and diabetes are not simply coexisting risk factors but function as the dominant population-level drivers of contemporary cardiovascular epidemiology [7, 8]. Together, they define the metabolic substrate upon which most cardiovascular events emerge and cluster. Hypertension prevalence among U.S. adults is projected to rise from approximately half of the population to 61% by 2050, translating into tens of millions of additional individuals exposed to cumulative vascular risk and an annual economic burden exceeding $130 billion (Table 2).

Table 2.

Hypertension

Measure	Estimate	Notes
Overall prevalence (adults)	≈ 32% (~ 85 million)	Based on measured BP and/or antihypertensive use
Lifetime risk	> 75%	Hypertension develops in the majority of adults with aging
Projected prevalence (2050)	61% of US adults	Driven by population aging, obesity, and CKM progression
Awareness rate	≈ 75–80%	Substantial fraction remains unaware of diagnosis
Treatment rate	≈ 65–70%	Reflects prescription of antihypertensive therapy
BP control (overall)	≈ 48%	Declined from > 54% in 2013–2014
BP control (treated)	≈ 60%	Indicates suboptimal intensification and adherence
Temporal trend since 2020	Worsening control	Despite stable prevalence
Racial and ethnic disparities	Persistent	Later treatment initiation and lower use of guideline-recommended therapy in Black and Hispanic adults
Mean SBP at treatment initiation	Higher in minoritized groups	Suggests delayed diagnosis and therapeutic inertia
Contribution to CVD burden	Primary modifiable risk factor	Major driver of stroke, HF, CKD, and ASCVD
Attributable mortality	Leading global CVD risk	Strong dose–response relationship with BP levels
Annual direct + indirect cost	≈$131 billion	Largest cost components: medications and office-based care
Population impact	High	Small BP shifts yield large population-level risk reduction

ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease; CKM: Cardiovascular–kidney–metabolic; HF: Heart failure

Diabetes exerts a similarly profound influence, affecting roughly 38 million U.S. adults, with an additional 96 million meeting criteria for prediabetes, effectively expanding the at-risk pool well beyond those with overt disease (Table 3). Notably, among treated adults with diabetes, mean HbA1c has worsened since 2020, accompanied by a marked decline in glycemic control rates, mirroring the parallel deterioration observed in blood pressure control over the same period [1, 9]. These converging trends illustrate a central paradox of modern cardiovascular medicine: therapeutic armamentaria have expanded and efficacy at the individual level is well established, yet population-level effectiveness continues to erode. The data therefore implicate systemic failures in long-term risk factor detection, treatment intensification, adherence, and continuity of care, rather than limitations of pharmacologic innovation itself.

Table 3.

Diabetes mellitus

Measure	Estimate	Notes
Overall prevalence (adults)	≈ 11% (~ 38 million)	Includes diagnosed and undiagnosed diabetes; strong bidirectional link with CVD
Diagnosed diabetes	≈ 29.5 million (10.6%)	Based on NHANES 2021–2023
Undiagnosed diabetes	≈ 9.6 million (3.5%)	Reflects substantial gaps in detection
Prediabetes prevalence	≈ 96 million adults (37.2%)	Large upstream reservoir for future diabetes and CVD
Incident diabetes (annual)	≈ 1.2 million new cases	Ongoing expansion of disease burden
Mean HbA1c (treated adults)	7.6%	Significant worsening since 2017–2020
Glycemic control rate	≈ 43.5%	Declined from > 50% earlier in the decade
Association with CVD	Major independent risk factor	Amplifies risk of CHD, stroke, HF, CKD
Annual economic burden	$413.6 billion	Combined direct medical costs and indirect productivity losses
Projected trend	Increasing through 2050	Driven by aging, obesity, and CKM syndrome prevalence

Diabetes is defined by one or more of the following criteria: a fasting plasma glucose (FPG) level of at least 126 mg/dL; a 2-hour post-challenge glucose level of at least 200 mg/dL during an oral glucose tolerance test; a random plasma glucose level of at least 200 mg/dL in the presence of symptoms of hyperglycemia; or HbA1c level of at least 6.5%

Prediabetes is defined by an FPG of 100–125 mg/dL, a 2-hour post-challenge glucose of 140–199 mg/dL during an oral glucose tolerance test, or HbA1c level of 5.7%–6.4%

NHANES = National Health and Nutrition Examination Survey

CKM syndrome: conceptual integration and prognostic insight

The introduction of cardiovascular–kidney–metabolic (CKM) syndrome is arguably the most important conceptual advance in the 2026 update [10]. As shown in Table 4, fewer than 11% of adults meet criteria for optimal CKM health, while nearly 15% have advanced multisystem disease. Notably, advanced CKM stages confer higher relative cardiovascular mortality risk in women than in men, a finding that challenges existing risk models and supports calls for sex-specific prevention strategies [1].

Table 4.

Cardiovascular–kidney–metabolic (CKM) syndrome

Measure	Estimate	Notes
Overall CKM prevalence	≈ 89%	Fewer than 1 in 8 U.S. adults meet criteria for optimal CKM health
Stage 0 prevalence	10.6%	Optimal CKM health; absence of metabolic, kidney, or cardiovascular disease
Stage 1 prevalence	25.9%	Early metabolic risk factors without overt organ damage
Stage 2 prevalence	49.0%	Established metabolic disease and/or early kidney or vascular involvement
Stages 1–2 combined	74.9%	Majority of adults have subclinical or established CKM disease
Stage 3 prevalence	5.4%	Overt CVD and/or CKD with high complication risk
Stage 4 prevalence	9.2%	Advanced multisystem disease with highest morbidity and mortality
Stages 3–4 combined	14.6%	Represents advanced, resource-intensive CKM burden
Prevalence of stages 3–4 in adults ≥ 65 y	> 55%	Disproportionate burden in older adults
Racial/ethnic disparity (advanced stages)	Highest in NH Black and AI/AN adults	Reflects cumulative exposure to structural and clinical risk
HR for CVD mortality (women)	8.23	Strong graded association across CKM stages
HR for CVD mortality (men)	6.88	Lower relative risk than women, but substantial absolute burden

AI: American Indian; AN: Alaska Native; NH: non-Hispanic

While a quantified economic burden is not yet available, the epidemiologic dominance of CKM syndrome suggests that future cardiovascular costs will increasingly be driven by multisystem disease rather than isolated cardiac pathology [11].

Coronary heart disease: epidemiologic stability, fiscal unsustainability

Prevalence and sex-specific patterns

Coronary heart disease (CHD) remains one of the most intensively studied cardiovascular conditions, yet its epidemiology has reached a plateau rather than a resolution. As shown in Table 5, CHD affects 15.9 million U.S. adults (5.2%), with numerically higher prevalence in men (6.9%) than women (3.7%), a difference long recognized and repeatedly confirmed [1, 12].

Table 5.

Coronary heart disease (CHD)

Measure	Estimate	Notes
Prevalence (overall)	5.2% (15.9 million)	Stable prevalence despite mortality decline
Prevalence in males	6.9%	Numeric sex-specific estimate
Prevalence in females	3.7%	Persistent sex gap
Annual economic burden	$239.9 billion	Largest CVD subtype cost

This relative stability in prevalence contrasts sharply with historical declines in acute myocardial infarction mortality, reinforcing the notion that improved survival has transformed CHD into a chronic condition rather than eliminating it.

The $239.9 billion annual cost attributed to CHD (Table 5) is the single largest disease-specific cardiovascular expenditure. This figure reflects not only acute care and revascularization but also decades of secondary prevention, recurrent hospitalizations, imaging, and pharmacotherapy.

From a health-systems perspective, CHD exemplifies the limitations of a strategy focused predominantly on downstream intervention rather than upstream risk modification [13].

Heart failure: the expanding end stage of cardiometabolic disease

Rapid growth in prevalence

Heart failure (HF) has emerged as the fastest-growing cardiovascular phenotype. As summarized in Table 6, HF prevalence increased from 6.7 million to 7.7 million adults within less than five years, a rise that cannot be explained by demographic aging alone [1].

Table 6.

Heart failure (HF)

Measure	Estimate	Notes
Prevalence	7.7 million	Up from 6.7 M (2017–2020)
Annual deaths	89,795	All-listed HF deaths
Age-adjusted mortality rate	21.6 per 100,000	Continues upward trend
Annual economic burden	$30.7 billion	Healthcare + productivity losses

This increase reflects the cumulative effects of hypertension, diabetes, obesity, chronic kidney disease, and improved survival after myocardial infarction, precisely the constellation of factors now captured within the CKM syndrome framework.

Despite therapeutic advances, HF remains associated with nearly 90,000 deaths annually and a rising age-adjusted mortality rate (Table 6). The $30.7 billion annual economic burden likely underrepresents the true cost, as it does not fully capture long-term disability, skilled nursing care, or informal caregiving.

Recent data underscore the growing burden of obesity as a central determinant of cardiovascular risk in the United States [14]: ~42.5% of U.S. adults had obesity (BMI > 30) in 2022, up from approximately 19% in 1990, with prevalence projected to reach nearly 47% by 2035, translating to more than 126 million individuals; notably, roughly 75% of adults are overweight (BMI > 25). At first glance, these trends suggest declining population health. However, historical context reveals a more nuanced picture: in the 1980s and early 1990s, lower obesity prevalence coincided with substantially higher cardiovascular mortality, widespread smoking, and limited preventive or therapeutic options, such that many individuals died before manifesting chronic metabolic disease [15]. Over the past four decades, improvements in cardiovascular treatment and preventive strategies have extended life expectancy, but this has occurred alongside rising rates of obesity, diabetes, and related metabolic disorders. These data highlight that today’s cardiometabolic epidemic is shaped by systemic factors (including food environments dominated by ultra-processed products, low health literacy, misaligned corporate incentives, and a healthcare system geared more toward disease management than prevention) rather than individual behavior alone. While new therapies, including GLP-1 receptor agonists, offer meaningful risk reduction, they address consequences rather than upstream causes. Obesity, therefore, should be viewed not as a moral or individual failure, but as a signal of structural vulnerabilities in public health, nutrition, and policy priorities. Integrating these findings into cardiovascular epidemiology emphasizes the need for preventive strategies and structural interventions to curb long-term population-level risk.

The epidemiology of HF thus challenges the field to reconsider whether current care models (largely reactive and hospitalization-centered) are appropriate for a disease that is predictable, progressive, and preventable in principle [16].

Stroke: declining Incidence, exploding prevalence

Stroke epidemiology illustrates the consequences of demographic momentum. While incidence rates have declined, particularly among White adults [1], prevalence is projected to double from 9.7 million to 19.4 million by 2050 (Table 7). This phenomenon reflects improved survival and population aging rather than a resurgence of cerebrovascular risk [17], yet its implications are profound.

Table 7.

Stroke

Measure	Estimate	Notes
Prevalence	3.9% (9.7 million)	Stroke survivors
Projected prevalence	6.4% (19.4 million)	Driven by population aging
Incidence (White adults)	170 per 100,000	Down from 215 (1993)
Incidence (Black adults)	311 per 100,000	Down from 349 (1993)
Annual economic burden	$30.5 billion	Projected $350.6B by 2050

The projected increase in stroke-related costs (from $30.5 billion in 2020 to $350.6 billion by 2050) represents one of the steepest cost curves in the entire report (Table 7). These costs are driven not by acute hospitalization alone but by long-term disability, rehabilitation, and loss of independence, domains historically underemphasized in cardiovascular economics.

Atrial fibrillation: a lifetime risk condition

Prevalence and lifetime risk

Atrial fibrillation (AF) now affects over 10.5 million U.S. adults, with a lifetime risk approaching 31% in contemporary cohorts (Table 8), denoting a substantial increase compared with earlier generations and reflects aging, obesity, hypertension, and enhanced detection [1, 18]. AF thus occupies a unique epidemiologic position: common, often silent, and profoundly consequential due to its association with stroke and heart failure.

Table 8.

Atrial fibrillation (AF)

Measure	Estimate	Notes
Prevalence (diagnosed AF)	4.48% (10.55 million)	Excludes undiagnosed AF
Lifetime risk (2000–2010)	24.2%	Earlier cohorts
Lifetime risk (2011–2022)	30.9%	Marked increase over time
Annual economic burden	$26.0 billion	Hospital + outpatient care

The $26 billion annual cost of AF (Table 8) is driven largely by hospitalizations, anticoagulation management, and procedural interventions [19]. Importantly, these figures exclude the downstream costs of AF-related stroke, which are accounted for separately, leading to systematic underestimation of AF’s true economic footprint.

Understudied conditions: PAD, valvular disease, and cardiac arrest

The absence of robust prevalence and cost estimates for peripheral artery disease, valvular heart disease, and sudden cardiac arrest is itself revealing. These gaps reflect systematic underdiagnosis, fragmented surveillance, and historical neglect, rather than limited clinical importance. In particular, PAD and degenerative valve disease disproportionately affect older adults and those with CKM risk factors [20], positioning them as future growth areas of cardiovascular burden.

Conclusion: knowledge is no longer the limiting factor

The 2026 AHA Statistics Update leaves little ambiguity: CVD is becoming more prevalent, more chronic, and more expensive, despite unprecedented scientific progress. The limiting factor is no longer knowledge or technology, but implementation, integration, and policy alignment.

Without a decisive shift toward primordial prevention, structural interventions, and integrated cardiometabolic care, future statistical reports will continue to document rising prevalence and escalating costs, an outcome that is epidemiologically predictable and ethically difficult to justify. While biomedical discovery has vastly expanded our understanding of cardiovascular disease, the limiting factor is no longer knowledge or technology, but implementation, integration, and policy alignment. Despite modest improvements in age-adjusted death rates, someone in the U.S. dies of cardiovascular disease every 34 s, and the absolute burden persists at historically high levels. These sobering statistics highlight that scientific knowledge alone is insufficient; we must develop and implement coordinated prevention strategies, cross-sector public health integration, and policy-driven approaches to primordial prevention (such as tobacco and sugar-sweetened beverage taxation, community-based lifestyle interventions, and health system performance metrics) to meaningfully shift population risk and reduce the cardiometabolic disease burden across diverse communities.

Author contributions

GS wrote the manuscript.

Funding

Prof. Gaetano Santulli, MD, PhD, FAHA is supported in part by the National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI: R01-HL146691, R01-HL164772, R01-HL159062), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK123259, R01-DK033823), and by the American Heart Association (AHA, 24IPA1268813).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics and consent to participate

Not applicable.

Competing interests

Prof. Santulli is the Editor-in-Chief of Cardiovascular Diabetology - Endocrinology Reports and was not involved handling this manuscript during the submission and the review processes.